Zura Bio Limited (NASDAQ:ZURA) Receives $14.33 Average Price Target from Brokerages

Shares of Zura Bio Limited (NASDAQ:ZURA - Get Free Report) have been given a consensus recommendation of "Buy" by the eight research firms that are presently covering the firm, MarketBeat reports. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $14.33.

A number of research firms recently commented on ZURA. HC Wainwright restated a "buy" rating on shares of Zura Bio in a report on Thursday, April 3rd. Chardan Capital dropped their price objective on Zura Bio from $12.00 to $10.00 and set a "buy" rating on the stock in a report on Wednesday, March 26th. Oppenheimer dropped their price objective on Zura Bio from $19.00 to $17.00 and set an "outperform" rating on the stock in a report on Friday, May 9th. Finally, Guggenheim restated a "buy" rating and issued a $15.00 price objective on shares of Zura Bio in a report on Wednesday, March 26th.

Zura Bio Price Performance

NASDAQ:ZURA traded up $0.04 during mid-day trading on Friday, reaching $1.04. The stock had a trading volume of 201,386 shares, compared to its average volume of 411,721. The business's 50 day moving average is $1.23 and its 200 day moving average is $1.81. Zura Bio has a fifty-two week low of $0.97 and a fifty-two week high of $5.56. The stock has a market cap of $70.77 million, a P/E ratio of -1.48 and a beta of 0.05.

Zura Bio (NASDAQ:ZURA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.02). Equities analysts expect that Zura Bio will post -0.65 EPS for the current year.

Institutional Trading of Zura Bio

Several large investors have recently modified their holdings of ZURA. JPMorgan Chase & Co. boosted its holdings in shares of Zura Bio by 12,060.8% during the 4th quarter. JPMorgan Chase & Co. now owns 2,633,185 shares of the company's stock worth $6,583,000 after buying an additional 2,611,532 shares during the period. ADAR1 Capital Management LLC boosted its holdings in shares of Zura Bio by 34.9% during the 1st quarter. ADAR1 Capital Management LLC now owns 2,801,184 shares of the company's stock worth $3,614,000 after buying an additional 723,933 shares during the period. Allostery Investments LP grew its stake in shares of Zura Bio by 44.2% in the first quarter. Allostery Investments LP now owns 2,329,384 shares of the company's stock worth $3,005,000 after acquiring an additional 714,258 shares during the last quarter. Millennium Management LLC grew its stake in shares of Zura Bio by 1,499.0% in the fourth quarter. Millennium Management LLC now owns 701,278 shares of the company's stock worth $1,753,000 after acquiring an additional 657,420 shares during the last quarter. Finally, Boxer Capital Management LLC acquired a new stake in shares of Zura Bio in the fourth quarter worth $750,000. 61.14% of the stock is owned by institutional investors.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.